Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr

Pharmaceutical company Ranbaxy Labs is anticipated to report a PAT of Rs 140 cr in the 3rd qtr of 2011 compared to Rs 308 cr in a yr ago period.

Income are seen rising 8percent to Rs 2,091 cr compared to Rs 1,935 cr while the similar period.

EBITDA is likely to bounce 28percent to Rs 177 cr in July-September qtr of 2011 compared to Rs 139 cr in the similar qtr of last financial.

Operating_profit margin is anticipated to be at 8.5percent compared to 7percent yoy.

Be Sociable, Share!
Tags:

Stock Market Basics For Beginners

Average

Average A share market average is known as a mathematical method of reporting the composite difference in prices of the shares that the average includes. Each and ...…

Who controls the Securities Market?

Who controls the Securities Market? The responsibility for controlling the securities-market is shared by DEA (Department of Economic Affairs), DCA (Department of Company Affairs ), RBI (Reserve Bank of India ...…

4 Blunders To Avoid While Stock Markets Fall

4 Blunders To Avoid While Stock Markets Fall The current outlook on the market seems utmost pessimistic on concerns of High crude oil prices, inflation, high interest hurting corporate earnings etc. Analyst on ...…

Who makes the Offer Documents / Prospectus?

Who makes the Offer Documents / Prospectus? Commonly, the public issues of firms are maintained by "Merchant Bankers" who are accountable for obtaining the project estimated, finalizing the value of the projects, ...…

Delisting of securities

Delisting of securities The word 'Delisting of securities' indicates permanent elimination of securities of a listed firm from a stock exchange. As a result of delisting, the securitie's ...…

Indian Share Tips

NSE Investment Site

Market Update

Share Guide

Designed by VMV
web
analytics